logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12620469 B1

PDFFull Text
Date of Patent:
May. 05, 2026

Filed:

Dec. 16, 2020

Therapeutic zone assessor

Applicant:

Dexcom, Inc., San Diego, CA (US);

Inventor:

Stephen D. Patek, Charlottesville, VA (US);

Assignee:

Dexcom, Inc., San Diego, CA (US);

Attorney:

Klarquist Sparkman, LLP

Primary Examiner:

Kambiz Abdi

Assistant Examiner:

Tran N Nguyen

Int. Cl.
CPC ...
G16H 20/17 (2018.01); A61B 5/00 (2006.01); A61B 5/145 (2006.01); G06F 16/26 (2019.01); G06F 40/40 (2020.01); G16H 10/60 (2018.01); G16H 15/00 (2018.01); G16H 20/10 (2018.01); G16H 20/60 (2018.01); G16H 40/67 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 50/70 (2018.01); G16H 70/40 (2018.01); A61M 5/172 (2006.01);
U.S. Cl.
CPC ...
G16H 20/17 (2018.01); A61B 5/14532 (2013.01); A61B 5/7275 (2013.01); G06F 16/26 (2019.01); G06F 40/40 (2020.01); G16H 10/60 (2018.01); G16H 15/00 (2018.01); G16H 20/10 (2018.01); G16H 20/60 (2018.01); G16H 40/67 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 50/70 (2018.01); G16H 70/40 (2018.01); A61M 5/1723 (2013.01); A61M 2230/201 (2013.01);
Abstract

Systems and methods are provided for identifying therapeutic zones where there is glycemic dysfunction of a specific type that can be addressed by making strategic changes to behavior and/or therapy parameters. Systems and methods described herein evaluate large historical data sets to: identify a therapeutic zone or zones with glycemic dysfunction that are most readily addressable; quantify the glycemic impact of a plurality of different therapeutic adjustments in terms of either adjustments to historical doses or the parameters of a prospective dosing strategy to determine the highest possible improvement; and/or identify patient dosing strategies to provide therapy recommendations adapted for the patient's preferred behavioral dosing strategy.

Find Patent Forward Citations

Loading…